OnKure Therapeutics, Inc. — Director's Dealing 2021

Apr 8, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Reneo Pharmaceuticals, Inc. (RPHM)
CIK: 0001637715
Period of Report: 2021-04-08

Reporting Person: Novo Holdings A/S (10% Owner)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
SERIES B CONVERTIBLE PREFERRED STOCK	$		COMMON STOCK (2763711)		Direct

Footnotes

F1: Each share of Series B Convertible Preferred Stock is convertible into common stock at a ratio of 1:4.4748 into the number of shares of common stock as shown in Column 3 at any time at the holder's election, and automatically upon the closing of the Issuer's initial public offering without payment of additional consideration. These shares have no expiration date.